Atopic Keratoconjuctivitis - Pipeline Insight, 2024

This “Atopic Keratoconjuctivitis - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atopic Keratoconjuctivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Atopic Keratoconjuctivitis Understanding

Atopic Keratoconjuctivitis: Overview

Atopic Keratoconjuctivitis (AKC) is a noninfectious chronic inflammatory ocular-surface condition associated with other atopic conditions. AKC may occur at any time after the onset of the associated dermatitis or other atopic condition, and is not necessarily correlated with exacerbations of these conditions.

Symptoms
The symptoms of Atopic Keratoconjuctivitis include:

• Sensitivity to eye
• Itching
• Burning
• Tearing
• Red and hardened eyelids

Diagnosis
Atopic Keratoconjuctivitis usually is diagnosed by clinical exam and a medical and family history. A conjunctival biopsy may be helpful in distinguishing AKC from other conditions.

Treatment
Combinations of oral and topical antihistamines and mast cell stabilizers usually are effective in controlling symptoms. In more severe cases, there is potential for damage to the eye caused by scratching and rubbing. Cold compresses and saline irrigation to lower the elevated tear pH also may be helpful. Only in severe cases topical steroid therapy should be considered. Steroid-sparing agents such as cylosporine or tacrolimus may be helpful. Systemic treatment of the conditions that accompany AKC may be very helpful.

Atopic Keratoconjuctivitis Emerging Drugs Chapters

This segment of the Atopic Keratoconjuctivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atopic Keratoconjuctivitis Emerging Drugs

r VA576: Akari Therapeutics rVA576 is currently in Phase I/II of clinical trial study and is being developed by Akari Therapeutics for the treatment of Atopic Keratoconjuctivitis. Thye trial got initiated in February 2019 and is expected to get completed by February2021.

Atopic Keratoconjuctivitis: Therapeutic Assessment

This segment of the report provides insights about the different Atopic Keratoconjuctivitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Atopic Keratoconjuctivitis

There are approx. 10+ key companies which are developing the therapies for Atopic Keratoconjuctivitis. The companies which have their Atopic Keratoconjuctivitis drug candidates in the most advanced stage, i.e. phase I/II include, Akari Therapeutics.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Atopic Keratoconjuctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atopic Keratoconjuctivitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atopic Keratoconjuctivitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atopic Keratoconjuctivitis drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Keratoconjuctivitis R&D. The therapies under development are focused on novel approaches to treat/improve Atopic Keratoconjuctivitis.

Atopic Keratoconjuctivitis Report Insights

• Atopic Keratoconjuctivitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Atopic Keratoconjuctivitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Atopic Keratoconjuctivitis drugs?
• How many Atopic Keratoconjuctivitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atopic Keratoconjuctivitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atopic Keratoconjuctivitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atopic Keratoconjuctivitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Akari Therapeutics
• Allakos

Key Products

• rVA576
• AK002

This product will be delivered within 2 business days.